Reckitt Reorganizes To Develop Health Care, Emerging Markets
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.
You may also be interested in...
Europe Continues To Drag On Reckitt Despite Boost From SSL
European sales continue to drag on Reckitt Benckiser even as newly acquired SSL brands contribute heavily to growth, the firm reports July 25.
Reckitt Continues Asian Push With $724M Paras Purchase
Reckitt Benckiser continues expanding its Asian business with the purchase of Paras Pharmaceuticals Ltd., a top OTC manufacturer in India, where nonprescription drug sales are growing 23% annually.
Coalition Pushes Congress On OTC Purchases With Health Savings Accounts
The Health Choices Coalition sent letters urging House and Senate members to support legislation that would strike the health care reform law requirement that consumers obtain a prescription in order to purchase OTCs with a pre-tax savings account.